Kolon TissueGene, Inc.
Developing cell and gene therapies for orthopedic and degenerative disorders.
950160 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 9713 Key West Ave Suite 300, Rockville
- Website:
- https://www.tissuegene.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Kolon TissueGene, Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
